Who are Intravenous Cisplatin & etoposide's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/intravenous-cisplatin-etoposide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Intravenous Cisplatin & etoposide — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intravenous Cisplatin & etoposide (Intravenous Cisplatin & etoposide) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapy combination (alkylating agent + topoisomerase II inhibitor). Area: Oncology.

phase 3 Chemotherapy combination (alkylating agent + topoisomerase II inhibitor) DNA (cisplatin: DNA cross-linking; etoposide: topoisomerase II) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Intravenous Cisplatin & etoposide (Intravenous Cisplatin & etoposide) — Swami Rama Cancer Hospital and Research Institute. Cisplatin and etoposide are chemotherapy agents that work together to damage cancer cell DNA and prevent cell division, leading to cancer cell death.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Intravenous Cisplatin & etoposide TARGET	Intravenous Cisplatin & etoposide	Swami Rama Cancer Hospital and Research Institute	phase 3	Chemotherapy combination (alkylating agent + topoisomerase II inhibitor)	DNA (cisplatin: DNA cross-linking; etoposide: topoisomerase II)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapy combination (alkylating agent + topoisomerase II inhibitor) class)

Swami Rama Cancer Hospital and Research Institute · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Intravenous Cisplatin & etoposide — Competitive Intelligence Brief. https://druglandscape.com/ci/intravenous-cisplatin-etoposide. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab